Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Late last month, Malaysia's government issued a compulsory license in an effort to offer a less-expensive version of Gilead's hepatitis C drug and increase access.
Reports of the government move in Malaysia coincided with Gilead's decision on 24 August to extend its voluntary licenses on its hepatitis C medicines to include Malaysia, Ukraine and Belarus.
Previously, the company signed agreements with 11 India-based manufacturers to make generics of its hepatitis C medicines for 91 developing countries.
One of the reasons countries can be hesitant to issue compulsory licenses is that they can be put on a US watch list that points out countries that "deny adequate and effective protection of intellectual property rights," or that "deny fair and equitable market access to United States persons that rely upon intellectual property protection," though the issuance of compulsory licenses is permissible under international law.
And the case for issuing a compulsory license in Malaysia (a move the country has also made previously to increase access to generic HIV drugs more than a decade ago) was made in a recent report that discussed the impact of that first issuance.
The report says this first compulsory license and the subsequent importation of generic HIV medicines reduced the average cost of treatment per month per patient from USD $315 to USD $58, and government treatment capacity increased from 1,500 to 4,000 patients.
"While the Malaysian government has been offered the price of USD $12,000 [for Gilead's sofosbuvir or Sovaldi], bioequivalent generics are available for much less i.e. USD $200-1000, and this means that patients will not be able to access these generics until the expiry of the monopolies," the report contended.
The report also highlighted Ukraine's challenges and legal battles with Gilead over the intellectual property of sofosbuvir.
Meanwhile, some are saying Gilead only decided to include Malaysia in its voluntary license program because the government issued a compulsory license.
In an op-ed in Malaysia's Star published Monday, Martin Khor, executive director of the intergovernmental organization known as the South Centre, said the gov
Tags: Malaysia, Gilead, Hepatitis C, compulsory license